FARSB Antibody

What is FARSB and why is it important in cellular biology?

FARSB is the beta subunit of phenylalanine-tRNA ligase (also called phenylalanyl-tRNA synthetase), which plays a critical role in protein synthesis by catalyzing the attachment of phenylalanine to its cognate tRNA. This aminoacyl tRNA synthetase is fundamental to translation accuracy and cellular protein homeostasis. Recent studies have demonstrated that FARSB expression is dysregulated in certain cancers, suggesting roles beyond its canonical function in protein synthesis. Understanding FARSB's cellular functions provides insight into both normal physiological processes and pathological mechanisms .

What types of FARSB antibodies are currently available for research?

Currently, the primary types available are rabbit polyclonal antibodies against human FARSB. These include antibodies targeting different epitopes such as N-terminal regions and other specific domains of the protein. Commercial options include antibodies validated for various applications such as Western Blot (WB), Immunohistochemistry (IHC), and Immunofluorescence (IF/ICC). The concentrations typically range from 0.1 mg/ml to 0.2 mg/ml depending on the manufacturer and specific product formulation .

What is the molecular weight of FARSB and how does this affect antibody detection?

FARSB has a calculated molecular weight of approximately 66 kDa, which is important to consider when performing Western blot analysis. When selecting antibodies, researchers should ensure they detect the appropriate molecular weight band. Some post-translational modifications may alter the apparent molecular weight on SDS-PAGE gels, so validation with positive controls is essential. The full-length protein sequence contains 589 amino acids, and researchers should consider which epitope region an antibody targets when interpreting experimental results .

What are the validated applications for FARSB antibodies in current research?

FARSB antibodies have been validated for multiple experimental applications including:

For optimal results, each antibody should be validated in the researcher's specific experimental system as performance may vary by sample type and preparation method .

How should researchers optimize FARSB antibody protocols for immunohistochemistry?

When optimizing immunohistochemistry protocols for FARSB detection, researchers should consider several critical factors. First, appropriate antigen retrieval methods should be selected based on the fixation method—heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective for formalin-fixed samples. Blocking should include both protein blocking (3-5% BSA or serum) and peroxidase blocking if using HRP-based detection systems. Antibody concentration should be titrated, typically starting with dilutions between 1:10-1:50 for IHC-P applications. Incubation conditions (time, temperature) should be systematically optimized, with overnight incubation at 4°C often yielding the best signal-to-noise ratio. Each experiment should include both positive controls (tissues known to express FARSB, such as testis) and negative controls (primary antibody omission) .

What cross-reactivity considerations are important when using FARSB antibodies?

Cross-reactivity is an important consideration when selecting FARSB antibodies. Most commercial FARSB antibodies have been validated against human samples with predicted reactivity to mouse and rat. Some antibodies also show predicted cross-reactivity with pig, bovine, sheep, and rabbit samples, though experimental validation for these species is often less extensive. When studying non-human models, researchers should verify the homology between the target epitope sequence and the corresponding sequence in their species of interest. Additionally, antibodies raised against specific domains (such as N-terminal targeted antibodies) may have different cross-reactivity profiles compared to those targeting other regions. Researchers should perform careful validation studies including appropriate positive and negative controls before using FARSB antibodies in non-validated species .

How can researchers interpret FARSB expression patterns in cancer tissue samples?

Interpreting FARSB expression in cancer tissues requires a multifaceted approach. Research indicates that FARSB is upregulated in hepatocellular carcinoma (HCC) and gastric tumors, correlating with unfavorable prognosis. When analyzing expression patterns, researchers should consider cellular localization (primarily cytoplasmic), intensity of staining, and percentage of positive cells. Quantitative scoring systems should be employed for consistency across samples. Additionally, FARSB expression should be evaluated in context with clinical parameters and other molecular markers. Recent studies suggest that FARSB expression is negatively correlated with its promoter methylation level, indicating epigenetic regulation. Furthermore, FARSB expression correlates with tumor purity and immune cell infiltration patterns, suggesting potential roles in tumor microenvironment modulation. Researchers should use multiple detection methods (IHC, Western blot, RT-qPCR) to confirm expression changes and correlate results with patient outcomes for meaningful clinical interpretations .

What are the considerations for using FARSB antibodies in multiplex immunofluorescence studies?

When employing FARSB antibodies in multiplex immunofluorescence studies, researchers must address several technical challenges. First, careful selection of primary antibodies from different host species is essential to avoid cross-reactivity between secondary antibodies. If using multiple rabbit-derived antibodies (common for FARSB), sequential staining with direct labeling or tyramide signal amplification may be necessary. Researchers should perform single-stain controls alongside multiplex experiments to verify antibody performance and specificity. Additionally, proper spectral unmixing is crucial when fluorophores have overlapping emission spectra. The order of antibody application can significantly impact results, with less abundant targets often benefiting from earlier application in the sequence. Researchers should also consider the subcellular localization of FARSB (primarily cytoplasmic) when co-staining with markers of different cellular compartments. Finally, automated image analysis tools should be calibrated with appropriate controls to ensure accurate quantification of co-localization or expression patterns .

How do computational approaches integrate with FARSB antibody experimental data in cancer research?

Computational approaches can significantly enhance the interpretation of experimental FARSB antibody data in cancer research. Integration of antibody-based expression data with gene expression databases, methylation profiles, and clinical outcome data can reveal relationships between FARSB and disease progression. For example, researchers have used The Cancer Genome Atlas (TCGA) data alongside immunohistochemistry findings to correlate FARSB expression with survival outcomes in HCC. Computational methods like TIMER analysis have been employed to investigate relationships between FARSB expression, tumor purity, and immune cell infiltration. Machine learning approaches can help identify patterns in large datasets that may not be apparent in single-parameter analyses. Furthermore, pathway enrichment analysis of FARSB-correlated genes has revealed associations with cell cycle processes, providing insights into potential mechanisms of action. Researchers should employ rigorous statistical approaches when integrating antibody-derived data with computational results, including appropriate corrections for multiple testing and validation in independent datasets .

What are common issues in Western blot detection of FARSB and how can they be resolved?

When detecting FARSB via Western blot, researchers may encounter several challenges:

For optimal results, sample preparation should include complete denaturation of FARSB (66 kDa) using reducing conditions. Longer transfer times (90-120 minutes) may be required for efficient transfer of this relatively large protein. Additionally, membrane selection (PVDF vs. nitrocellulose) can significantly impact detection sensitivity and should be optimized for specific antibodies .

How can researchers validate the specificity of FARSB antibodies?

Validating FARSB antibody specificity requires a multi-faceted approach. First, researchers should perform Western blot analysis to confirm detection of a single band at the expected molecular weight (66 kDa) in tissues known to express FARSB. Comparative analysis with multiple antibodies targeting different epitopes of FARSB can provide additional confidence in specificity. Knockout/knockdown validation is the gold standard—comparing staining patterns between wild-type samples and those with FARSB expression suppressed via siRNA, shRNA, or CRISPR-Cas9. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, should eliminate specific staining. For immunohistochemistry applications, researchers should compare staining patterns with known FARSB expression data from RNA sequencing or proteomics studies. Additionally, antibodies should be tested across multiple applications (WB, IHC, IF) to ensure consistent detection patterns. Finally, cross-reactivity with similar proteins (like FARSA) should be evaluated, particularly when studying protein complexes or interactions .

What strategies can overcome weak signal issues in FARSB immunohistochemistry?

When facing weak signal issues in FARSB immunohistochemistry, researchers can implement several optimization strategies. First, antigen retrieval methods should be systematically tested—comparing heat-induced epitope retrieval using different buffers (citrate pH 6.0 vs. EDTA pH 9.0) and durations (10-30 minutes). Signal amplification systems such as polymer-based detection, tyramide signal amplification, or avidin-biotin complexes can significantly enhance sensitivity compared to standard secondary antibody detection. Primary antibody incubation can be extended (overnight at 4°C vs. 1 hour at room temperature) and concentration increased incrementally (starting from 1:10 dilution for IHC applications). Tissue fixation conditions should be evaluated, as overfixation can mask epitopes while underfixation may compromise tissue morphology. Fresh tissue sections (cut within 1-2 weeks) generally provide stronger signals than older sections. Finally, implementing automated IHC platforms with controlled conditions can improve consistency and signal intensity. Each modification should be tested systematically with appropriate positive controls known to express FARSB at different levels to establish optimal signal-to-noise ratios .

How is FARSB expression linked to cancer prognosis and what are the implications for antibody-based diagnostics?

Research demonstrates significant correlations between FARSB expression and cancer outcomes. In hepatocellular carcinoma (HCC), FARSB mRNA and protein levels are upregulated compared to normal tissues and correlate with multiple clinicopathological features. Multivariate Cox analysis has shown that high FARSB expression is associated with shorter survival time in HCC patients and may serve as an independent prognostic factor. These findings suggest potential utility for FARSB antibodies in prognostic assessment and patient stratification.

For antibody-based diagnostic applications, standardized scoring systems must be developed that account for staining intensity, percentage of positive cells, and cellular localization patterns. Quantitative image analysis algorithms can improve reproducibility of FARSB expression assessment. Researchers developing such applications should validate cutoff values for "high" versus "low" expression through rigorous statistical analysis of patient cohorts with complete follow-up data.

Additionally, the negative correlation between FARSB promoter methylation and expression suggests potential for combined methylation/protein expression assays to improve prognostic accuracy. Researchers should also consider FARSB's relationship with tumor immune infiltration when developing comprehensive prognostic panels, as TIMER analysis has revealed connections between FARSB expression, tumor purity, and immune cell populations .

What is known about FARSB's role in the cell cycle and how can antibodies help elucidate its function?

Enrichment analysis has revealed that FARSB is associated with cell cycle processes, though the specific mechanisms remain under investigation. This connection between a tRNA synthetase and cell cycle regulation suggests non-canonical functions beyond protein synthesis. FARSB antibodies can help elucidate these functions through several experimental approaches:

• Chromatin immunoprecipitation (ChIP) using FARSB antibodies can identify potential DNA binding sites or interactions with chromatin-modifying complexes.

• Co-immunoprecipitation (Co-IP) followed by mass spectrometry can reveal FARSB protein interaction partners involved in cell cycle regulation.

• Immunofluorescence co-localization studies can track FARSB distribution throughout different cell cycle phases.

• Proximity ligation assays (PLA) can confirm direct protein-protein interactions between FARSB and suspected cell cycle regulators in situ.

• Flow cytometry using FARSB antibodies in combination with cell cycle markers can quantitatively assess expression changes during different phases.

When conducting these experiments, researchers should employ synchronized cell populations to precisely track FARSB dynamics throughout the cell cycle. Correlating these findings with functional studies (e.g., FARSB knockdown/overexpression followed by cell cycle analysis) can establish causal relationships between FARSB and specific cell cycle processes .

How can researchers investigate the relationship between FARSB and immune cell infiltration using antibodies?

TIMER analysis has indicated that FARSB expression correlates with tumor purity and immune cell infiltration patterns, suggesting potential roles in tumor immune microenvironment regulation. To investigate these relationships, researchers can employ several antibody-based approaches:

• Multiplex immunofluorescence or immunohistochemistry using FARSB antibodies alongside markers for specific immune cell populations (CD3 for T cells, CD20 for B cells, CD68 for macrophages, etc.) can visualize spatial relationships between FARSB-expressing cells and immune infiltrates.

• Digital spatial profiling combining FARSB antibodies with immune cell markers can provide quantitative, spatially-resolved data on expression patterns and cellular interactions.

• Single-cell analysis techniques like mass cytometry (CyTOF) or imaging mass cytometry that incorporate FARSB antibodies can reveal heterogeneity within cell populations and identify specific immune cell subsets associated with FARSB expression.

• Laser capture microdissection guided by FARSB immunostaining followed by transcriptomic or proteomic analysis can characterize molecular features of FARSB-expressing cells and surrounding immune populations.

Researchers should analyze correlations between FARSB expression levels, immune cell densities, and clinical outcomes to establish functional significance. Additional mechanistic studies may include examining how modulation of FARSB expression affects immune cell recruitment, activation, or function in appropriate model systems. Careful selection of antibodies with minimal cross-reactivity is essential when performing these complex multi-parameter analyses .

How might computational antibody design approaches improve FARSB antibody development?

Recent advances in computational antibody design could significantly enhance FARSB antibody development. Physics- and AI-based computational pipelines have demonstrated success in discovering and designing therapeutic antibody candidates with improved properties. These approaches incorporate in silico biophysical property assessment, machine learning-based antibody design, and sample-efficient experimental validation to create high-affinity, developable antibodies.

For FARSB antibody development, computational methods could help design antibodies with:

• Enhanced specificity for particular epitopes or protein regions

• Improved developability profiles (reduced aggregation, increased thermostability)

• Cross-reactivity with specific species for comparative studies

• Optimized binding to particular FARSB conformations or complexes

The computational pipeline would involve generating structural models of FARSB epitopes, designing complementary binding regions in antibody variable domains, and evaluating biophysical properties before experimental validation. This approach could reduce the number of candidates requiring experimental testing, accelerating development timelines.

Additionally, iterative design cycles incorporating Bayesian optimization could further refine antibody properties based on experimental feedback. While these methods have shown promise in therapeutic antibody development against targets like SARS-CoV-2, their application to research antibodies against targets like FARSB represents an exciting frontier in research tool development .

What epigenetic regulation mechanisms control FARSB expression and how can antibodies help study them?

Studies have revealed that FARSB promoter methylation levels negatively correlate with FARSB expression, indicating important epigenetic regulatory mechanisms. Researchers can employ antibody-based approaches to further investigate these epigenetic controls:

• Chromatin immunoprecipitation (ChIP) using antibodies against histone modifications (H3K4me3, H3K27me3, H3K27ac) at the FARSB promoter can reveal active or repressive chromatin states.

• Methylated DNA immunoprecipitation (MeDIP) with 5-methylcytosine antibodies followed by qPCR or sequencing of the FARSB promoter region can quantify methylation levels.

• Co-immunoprecipitation using FARSB antibodies followed by mass spectrometry may identify epigenetic regulatory proteins that interact with FARSB.

• Dual immunofluorescence with FARSB antibodies and antibodies against DNA methyltransferases or histone-modifying enzymes can reveal spatial relationships in tissue contexts.

These approaches can be combined with functional studies manipulating methylation status (using DNMT inhibitors like 5-azacytidine) or histone modifications (using HDAC inhibitors) to establish causal relationships. Researchers should analyze these epigenetic patterns across different tissue types and disease states, particularly focusing on transitions from normal to cancerous tissue where FARSB expression increases. Properly validated antibodies against both FARSB and epigenetic marks are essential for reliable results in these complex studies .